Multi-Center Registry for ME/CFS

Condition(s) studied

Study summary

The ME/CFS study (MECFS-R) aims to create a large-scale registry that provides data on epidemiology, phenotypes, and disease trajectories of and health care for ME/CFS at any age in Germany, which can be used for future clinical trials.

Eligibility

Primary outcome measure(s)

• Phenotyping ME/CFS: Medical History — 30 years
  Routine assessment of the medical history, such as current and previous medication, vaccinations, comorbidities, and more, to achieve a profound ME/CFS phenotype.
• Assessment of routine physical examination findings — 30 years
  Routine physical examination to achieve a profound and detailed ME/CFS phenotype.
• Number of participants with abnormal laboratory tests results — 30 years
  Measurement of a routine set of laboratory parameters including blood tests (cell count\[cell/µl\], C-reactive protein \[mg/dl\], immunoglobulins A/M/G \[md/dl\], antinuclear antibodies \[titer\], etc.) and urine/stool analysis (e.g. calprotectin \[mg/kg\], positive hemoglobin in urine test stripe) to achieve a profound ME/CFS phenotype.
• Number of participants with abnormal technical exam results — 30 years
  Technical exams (e.g. restrictive and obstructive pattern in pulmonary function tests, conduction in electrocardiography, ultrasound imaging, magnetic resonance imaging, etc.) will be performed as indicated to achieve a profound and detailed ME/CFS phenotype.

Trial sites (1)

More Technical University of Munich trials in Germany

Other trials for the same condition